|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.04 USD | +2.59% |
|
-0.36% | -14.54% |
| 08:31am | Syndax Pharmaceuticals Reports Positive Data From Leukemia Combo Drug Trial | MT |
| Jun. 10 | Syndax Pharmaceuticals, Inc. - Shareholder/Analyst Call |
Business description: Syndax Pharmaceuticals, Inc.
Number of employees: 298
Sales by Activity: Syndax Pharmaceuticals, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology (Startups) | 140M | - | - | 23.68M | 172M |
Geographical breakdown of sales: Syndax Pharmaceuticals, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 140M | - | - | 23.68M | 172M |
Executive Committee: Syndax Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Metzger
CEO | Chief Executive Officer | 55 | 2022-02-02 |
Peter Ordentlich
CTO | Chief Tech/Sci/R&D Officer | 57 | 2013-10-31 |
Keith Goldan
DFI | Director of Finance/CFO | 54 | 2022-06-12 |
Nicholas Botwood
CTO | Chief Tech/Sci/R&D Officer | - | 2025-05-11 |
Sharon P. Klahre
IRC | Investor Relations Contact | - | 2022-06-12 |
Composition of the Board of Directors: Syndax Pharmaceuticals, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Podlesak
CHM | Chairman | 68 | 2008-11-30 |
Michael Metzger
BRD | Director/Board Member | 55 | 2019-07-03 |
Pierre Legault
BRD | Director/Board Member | 65 | 2017-01-03 |
Keith Katkin
BRD | Director/Board Member | 54 | 2017-03-28 |
Jennifer Jarrett
BRD | Director/Board Member | 55 | 2018-09-24 |
Martin Huber
BRD | Director/Board Member | 66 | 2021-09-14 |
Aleksandra Rizo
BRD | Director/Board Member | 51 | 2024-05-13 |
Company details: Syndax Pharmaceuticals, Inc.
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.59% | -0.36% | +64.72% | -13.43% | 1.56B | |
| -1.40% | +0.12% | -14.73% | -12.42% | 43.68B | |
| +3.93% | -4.37% | +264.99% | +488.23% | 30.65B | |
| -1.54% | -3.92% | +13.05% | -15.27% | 30.4B | |
| -1.39% | -7.04% | -0.83% | +22.05% | 29.31B | |
| -0.66% | -7.13% | +7.59% | +12.76% | 24.2B | |
| +1.42% | +2.94% | +56.19% | +116.57% | 13.3B | |
| +3.12% | -0.95% | - | - | 13.03B | |
| -1.65% | -1.08% | +7.92% | +8.03% | 13.21B | |
| +1.03% | -1.38% | +104.73% | +77.97% | 12.12B | |
| Average | +0.68% | -1.28% | +55.96% | +76.05% | 21.15B | |
| Weighted average by Cap. | +0.26% | -1.46% | +51.69% | +88.17% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SNDX Stock
- Company Syndax Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
